Navigation Links
New drug shrinks cancer in animals, U-M study shows
Date:4/6/2011

ANN ARBOR, Mich. A study led by researchers at the University of Michigan Comprehensive Cancer Center showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.

The study, done in two mouse models of human cancer, looked at two compounds designed to activate a protein that kills cancer cells. The protein, p53, is inactivated in a significant number of human cancers. In some cases, it is because another protein, MDM2, binds to p53 and blocks its tumor suppressor function. This allows the tumor to grow unchecked. The new compounds block MDM2 from binding to p53, consequently activating p53.

"For the first time, we showed that activation of p53 by our highly potent and optimized MDM2 inhibitors can achieve complete tumor regression in a mouse model of human cancer," says lead study author Shaomeng Wang, Ph.D., Warner-Lambert/Parke-Davis Professor in Medicine and director of the Cancer Drug Discovery Program at the U-M Comprehensive Cancer Center.

Wang presented the study at the American Association for Cancer Research 102nd annual meeting.

Many traditional cancer drugs also activate p53 but they do so by causing DNA damage in both tumor cells and normal cells, causing side effects. These new MDM2 inhibitors activate p53 while avoiding the DNA damage common with other drugs. In this study, which was done in collaboration with Ascenta Therapeutics and sanonfi-aventis, researchers showed that these new drugs shrank tumors without significant side effects.

Because p53 is involved in all types of human cancer, the new drug has potential to be used in multiple types of cancer. Further, the researchers also identified certain markers in tumors that predict which ones will be particularly sensitive to the MDM2 inhibitor, which would allow physicians to target the drug only to patients most likely to benefit.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Page: 1

Related medicine news :

1. Stem Cell Therapy Shrinks Enlarged Hearts
2. Smart drug targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer
3. Cholesterol-lowering drug shrinks enlarged prostates in hamster model
4. VCU study: Researchers discover a drug combination that shrinks tumors in vivo
5. As girth grows, risk of sudden cardiac death shrinks
6. Drug for advanced kidney cancer shrinks tumors prior to surgery
7. Fox Chase researchers find that fish oil boosts responses to breast cancer drug tamoxifen
8. Fox Chase researchers report that naproxen reduces tumors in a mouse model of colon cancer
9. Overall Health May Be Key to Beating Breast Cancer
10. Immune-Boost Treatment Might Help Some With Advanced Colon Cancer
11. An international study in China finds strawberries may slow precancerous growth in the esophagus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... ... work wear distributors and International relief organizations across the globe to provide effective ... offers lifestyle and work wear collections via insectshield.com . In the wake ...
(Date:4/24/2017)... ... April 24, 2017 , ... A 2-in-1 bottleless water ... place. From 101 Water Texas, here are the ways in which this technology ... continuous supply of pure, fresh, oxygenated water, with both cold and hot options. ...
(Date:4/23/2017)... ... April 23, 2017 , ... Altura Communication Solutions, ... of Cisco Select certification and SMB specialization. Altura is now qualified to ... In earning the Select Certification, Altura fulfilled the training and exam requirements for ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... has named PROSHRED® Security of Philadelphia its “Woman-Owned Small Business of ... specializes in providing information destruction , recycling, and compliance services to ...
(Date:4/22/2017)... New Freedom, PA (PRWEB) , ... April 22, ... ... of healthcare experience to his role as Vice President of Sales and Business ... direction of key GPO/IDN business partner engagements, business development, and strategic planning for ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
(Date:4/19/2017)... 19, 2017  New research provides evidence that an old ... to a study released today that will be presented at ... in Boston , April 22 to 28, ... of Parkinson,s disease, the oral drug levodopa has long been ... But as the disease progresses, the effects of the medication ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
Breaking Medicine Technology: